Spectral-domain OCT changes in retina and optic nerve in children with hypoxic–ischaemic encephalopathy

L. Grego 1,2 · S. Pignatto 1,2 · E. Busolini 3 · N. Rassu 1,2 · F. Samassa 1,2 · R. Prosperi 1,2 · C. Pittini 3 · L. Cattarossi 3 · Paolo Lanzetta 1,2

Received: 11 August 2020 / Revised: 8 October 2020 / Accepted: 23 October 2020 / Published online: 3 November 2020
© The Author(s) 2020

Abstract

**Purpose** To evaluate the effect of neonatal hypoxic–ischaemic injury on the retina and the optic nerve and to correlate ocular damage with systemic parameters, laboratory tests, neurological imaging and therapeutic hypothermia at birth.

**Methods** Forty-one children with hypoxic–ischaemic encephalopathy (HIE) at birth (9.09 ± 3.78 years) and a control group of 38 healthy subjects (9.57 ± 3.47 years) were enrolled in a cohort study. The HIE population was divided into three subgroups, based on the degree of encephalopathy according to Sarnat score and the treatment with therapeutic hypothermia (TH): Sarnat score I not treated with hypothermia, Sarnat score II-III treated with TH and Sarnat score II-III not subjected to TH. Total macular thickness, individual retinal layers and peripapillary nerve fibre layer thickness were measured with spectral-domain optical coherence tomography. Clinical data of perinatal period of HIE children were collected: APGAR score, pH and base excess of funiculus blood at birth, apnoea duration, brain ultrasound, cerebral MRI ischaemic lesions and blood chemistry tests.

**Results** Children with Sarnat score I did not show a reduction of peripapillary nerve fibres and ganglion cell layer compared to the control group \((p = 0.387, p = 0.316)\). Peripapillary nerve fibre layer was 109.06 ± 7.79 \(\mu m\) in children with Sarnat score II-III treated with TH, 108.31 ± 7.83 \(\mu m\) in subjects with Sarnat score II-III not subjected to TH and 114.27 ± 6.81 \(\mu m\) in the control group \((p = 0.028, p = 0.007)\). Ganglion cell layer was thinner in children with Sarnat score II-III treated with TH (50.31 ± 5.13 \(\mu m\)) compared to the control group (54.04 ± 2.81 \(\mu m\)) \((p = 0.01)\). Inner retinal layers damage correlated with C-reactive protein and lactate dehydrogenase increase, while higher levels of total bilirubin were protective against retinal impairment \((p < 0.05)\). Cerebral oedema was related to peripapillary nerve fibre layer thickness \((p = 0.046)\).

**Conclusions** Thickness reduction of inner retinal layer and peripapillary nerve fibre impairment was related to encephalopathy severity. Ocular damage was associated with inflammation and cerebral oedema following hypoxic–ischaemic damage.

Key messages

- Visual loss associated with brain damage is a main cause of visual impairment in children. It can be caused by several injuries, the most frequent of which is hypoxic ischemic encephalopathy (HIE). Central nervous system damage has been suspected as the only cause of visual impairment in HIE, but recently retinal and optic nerve damages have been found to participate to loss of vision.

- Our study is the first to assess with SD-OCT long-term retinal and optic nerve damage in children with neonatal HIE.

- Inner retinal layers and peripapillary nerve fibers thickness are reduced in children with neonatal HIE compared to healthy population.

- Retinal and optic nerve damage in HIE children correlates with the severity of encephalopathy.
Introduction

Neonatal hypoxic–ischaemic encephalopathy (HIE) is a clinical syndrome characterised by abnormal neurologic behaviour in the neonatal period due to inadequate blood flow and oxygen provision to the brain as a result of hypoxic–ischaemic events [1, 2]. Sarnat score divides HIE into three clinical stages (mild—grade I, moderate—grade II and severe—grade III), based on different parameters: level of consciousness, neuromuscular control, complex reflexes, autonomic nervous system activity, seizures and electroencephalogram findings [3]. The standard of care for moderate and severe HIE includes therapeutic hypothermia (TH), which reduces core temperature to 33 °C–34 °C, with neuroprotective effects. Currently, two methods of TH are used: selective head cooling and whole-body cooling [4]. TH reduces the risk of mortality, neurodevelopment delay, blindness and cerebral palsy at 18 months. Although TH improves neurological outcomes in children with HIE, it does not provide complete protection: about 30% of treated children present different degrees of disability at 18 months of life [2, 5].

In developed countries, the most common cause of visual impairment is brain damage. It can be associated with several injuries, such as hypoglycaemia, epileptic seizures and hydrocephalus, although the most frequent cause is the hypoxic–ischaemic damage at birth [6]. Loss of visual function in HIE children have been primarily associated to hypoxic–ischaemic lesions of visual cortex in the occipital lobe, hence the term cortical blindness. This assertion has been questioned due to poor correlation between the degree of occipital cortex alterations, identified by computed tomography (CT) and nuclear magnetic resonance (MRI) and the severity of visual impairment [7–9]. Visual disability is strongly related to damaged visual associative areas, located in the temporal and parietal cortices, and visual attention pathways, located in the frontal lobe. White matter damage (periventricular leukomalacia and optical radiation impairments) contributes to visual dysfunction in HIE children [6] [10]. Currently, several studies are analysing retinal alterations associated with HIE in animal models, evaluating whether visual impairment could originate from a direct retinal damage as well as central nervous system lesions [11]. Inner retinal layer damage was detected in HIE mice, and TH seemed to have a protective effect on ganglion cell layer in asphyctic mice, preserving the retinal structure [11–13]. Few data are available in HIE children about retinal and optic nerve damage, always collected in aftermath of acute hypoxic insult. Retinal and choroidal thinning, associated with subretinal fluid, was detected with spectral-domain optical coherence tomography (SD-OCT) in HIE newborns [14]. Other findings identified with SD-OCT in asphyctic children are perimacular cystoid spaces, ganglionar cell and peripapillary nerve fibre layer thinning [15]. So far, no studies evaluated retinal and optic nerve long-term outcomes after neonatal HIE.

The primary purpose of our study is to evaluate long-term retinal and peripapillary nerve fibre alterations with SD-OCT in children with HIE at birth, comparing them with a control group without neonatal asphyxia. The secondary purpose is to identify whether the ocular alterations correlate with systemic parameters at birth, laboratory data and radiological imaging of the central nervous system in perinatal period.

Materials and methods

A cohort study was conducted at the Clinica Oculistica and at the Patologia Neonatale-Azienda Sanitaria Universitaria Friuli Centrale (ASUFC)-Ospedale Santa Maria della Misericordia, Udine, Italy, between February and September 2019. The study is adherent to the tenets of 1964 Helsinki declaration, and it is in accordance with the standards of the regional ethics committee (CEUR).

Forty-one children with diagnosis of HIE at birth (HIE group) and 38 healthy children (control group, CTL group), aged between 5 and 16 years, were enrolled. The population was born between January 2003 and September 2014.

Inclusion criteria for the HIE group were as follows: gestational age above 36 weeks, diagnosis of HIE performed at birth with neurologic examination and electroencephalogram, cycloplegic refractive error (calculated as spherical equivalent) between +3 and −3 dioptres. Exclusion criteria were congenital syndromes and severe disability resulting from the anoxic damage that precluded complete ophthalmological evaluation. Exclusion of children with a severe cerebral damage was due to the unavailability of a portable SD-OCT. Children not enrolled in the study presented higher degrees of mental and physical impairment, lowering significantly their compliance and precluding the use of traditional SD-OCT. No visual acuity cut off was set for HIE group.

Currently, recommendations prescribe TH in HIE children with Sarnat score II or III, while it is not recommended in newborn with Sarnat score I. In the Neonatal Intensive Care Unit of the Hospital of Udine, TH was available only from 2010. Therefore, children with Sarnat score II or III born before 2010 did not receive TH, while those with Sarnat score II or III born after 2010 were treated with TH. Thus, according to the degree of encephalopathy, availability and need of TH, HIE children were divided into three subgroups: Sarnat score I.
II–III treated with hypothermia (SII–II/TH–), Sarnat score II–III not treated with hypothermia (SII–III/TH–) and Sarnat score I that did not require treatment with hypothermia (SI/TH–). Sarnat III children were few in our population (2 in the hypothermic subgroup, 3 in the non-hypothermic subgroup). Due to the low number, it was not possible to create a subgroup with only Sarnat III children. Therefore, we grouped children with Sarnat II and III for the study.

Inclusion criteria for the CTL group were gestational age above 36 weeks and cycloplegic refractive error (calculated as spherical equivalent) between +3 and −3 dioptres. Exclusion criteria were amblyopia, strabismus or other eye conditions and presence of systemic diseases.

One eye from each subject was randomly selected for analysis, using a random number generator. Enrolled children underwent complete ophthalmological evaluation and orthoptic examination. Best corrected visual acuity was measured with Snellen tables or E charts. Cyclopentolate eye drops were administered twice within an interval of 5 min, and cycloplegic refraction was measured using Retinomax K-plus3 autorefractor (Righton), approximately 30 min after the second eye drop. Spherical equivalent (calculated as spherical error + half cylinder error) was obtained from the refractive error value for each eye. Slit-lamp biomicroscopy of the anterior segment and indirect ophthalmoscopy of the fundus were conducted.

SD-OCT (Heidelberg Engineering, Dossenheim, Germany) was performed after pupil dilation. Three maps of the macular region centred on the fovea, with 25 scans spaced 237 μm and a total area of 5700 × 5700 μm, were obtained. The highest quality map was chosen for analysis. Quality score was automatically assigned by SD-OCT software, expressed as signal-to-noise ratio in decibels. Scans over 20 dB were considered of high quality. Each scan of the 25 macular scans was automatically segmented to single out the profile and thickness of each individual retinal layer. Automatic segmentation of each scan was checked and manually corrected by two independent observers (L.G., S.P.). The following retinal layers were measured: macular nerve fibre layer (MNFL), ganglion cell layer (GCL), inner plexiform layer (IPL), inner nuclear layer (INL), outer plexiform layer (OPL), outer nuclear layer (ONL), retinal pigment epithelium (RPE), inner retinal layers (IRL) and outer retinal layers (ORL). Early Treatment Diabetic Retinopathy Study (ETDRS) grid evaluated the macular and individual retinal layers thickness, each divided into three zones: average thickness in the central square millimetre; average thickness of superior, temporal, inferior and nasal segments of the ring with 3 mm diameter and average thickness of superior, temporal, inferior and nasal segments of the ring of 6 mm diameter. For the purposes of our study, we considered the average of values of the SD-OCT ETDRS grid with 3 mm diameter (3 mm), 6 mm diameter (6 mm) and the mean of all segments of ETDRS grid (total).

Three circular scans of the peripapillary nerve fibre layer (PNFL) with a diameter of 3.5 mm were obtained. PNFL scans with the best image quality were chosen for the analysis. SD-OCT software automatically calculates PNFL thickness in the central, temporal, superior-temporal, superior-nasal, nasal, inferior-nasal and inferior-temporal sectors. Average values were used for the study.

Data regarding the perinatal period were obtained from the clinical data management system and the medical records for the HIE group: Sarnat score; gestational age; weight at birth; APGAR score at 1, 5 and 10 min of life; pH and base excess in funiculus blood at birth; arterial blood oxygen pressure, carbon dioxide pressure and lactates measured at the first sampling performed by entering in the Neonatal Intensive Care Unit; brain ultrasound alterations (hyperechogenicity of periventricular white matter, impaired white/grey matter differentiation and/or slit-like ventricles); cerebral MRI ischaemic lesions; apnoea duration and overall duration of respiratory assistance and latency of visual evoked potentials flashes (VEP) performed within the first 10 days of life. In addition, blood chemistry tests of the first 3 days were collected, including red blood cells, white blood cells, platelets, haemoglobin, haematocrit, mean corpuscular volume (MCV), mean corpuscular haemoglobin concentration (MCHC), C-reactive protein (CRP), urea nitrogen, creatinine, lactate dehydrogenase (LDH), serum glutamic oxaloacetic transaminase (SGOT), serum glutamic pyruvate transaminase (SGPT), total and direct bilirubin and albumin. For statistical analysis, the mean value of blood chemistry tests of the first three days was considered. Blood chemistry values for each day were not available for all patients, as they were performed according to the clinical status of HIE children. For CRP, the values of day 4 and 5 were evaluated in order to analyse the evolution over time.

Statistical analysis was conducted using SPSS Statistic version 22 (IBM Corporation). Normality of continuous variables was evaluated with the Shapiro–Wilk test. One-way ANOVA followed by multiple comparisons of Bonferroni and Kruskal Wallis tests followed by post hoc test were used to identify the differences in total retinal thickness, individual retinal layers thickness and PNFL between the encephalopathic patients and CTL group, respectively for normal and non-normal variables. Pearson and Spearman tests were used for the correlation of continuous systemic parameters (blood chemistry tests mean value of first three days of life) with MNFL, GCL and PNFL. It was not possible to perform repeated measures ANOVA or Friedman test to look for a correlation between haematochemical tests and retinal thickness over time, due to blood test data not being available for each day in all patients. T test and Mann–Whitney test were used for the correlation of dichotomous systemic parameters and MNFL, GCL and PNFL. p value < 0.05 was considered statistically significant.
Results

Characteristics of the population

Forty-one children with HIE at birth (mean age of 9.09 ± 3.78 years) were enrolled (HIE group). The population was divided into three subgroups, based on degree of encephalopathy and treatment with TH:

- SII-III/TH+ subgroup: 18 children with Sarnat score II-III treated with TH (mean age of 6.14 ± 0.91 years, 10 males and 8 females)
- SII-III/TH- subgroup: 12 children with Sarnat score II-III, no TH (mean age of 13.05 ± 2.62 years, 7 males and 5 females)
- SI/TH- subgroup: 11 children with Sarnat score I, no TH (mean age of 9.6 ± 3.67 years, 6 males and 5 females)

Thirty-eight healthy children (13 males and 25 females) with a mean age of 9.57 ± 3.47 years were enrolled as the CTL group. Age was not significantly different between the HIE group and the CTL group (p = 0.426), whereas this was significantly different in the subgroups (p < 0.05) (Fig. 1). Age difference between subgroups can be explained due to TH being performed based on the severity of HIE and TH being available in the Neonatal Intensive Care Unit from 2010: children of SII-III/TH- subgroup were born between 2003 and 2009 when TH was not available, children of SII-III/TH+ subgroup were born between 2010 and 2014 and where treated with TH, while the children of SI/TH -, that did not need TH, were born between 2003 and 2014.

Gestational age, birth weight, APGAR score, pH and base excess in funiculus blood at birth, arterial blood lactates and duration of apnoea are reported in Table 1. Mean PCR values of the HIE group in the first 5 days of life were the following: 3.52 ± 8.23 mg/l in the first day, 9.66 ± 10.68 mg/l in the second day, 20.97 ± 27.60 mg/l in the third day, 33.2 ± 57.56 mg/l in the fourth day and 27.96 ± 31.59 mg/l fifth day. LDH mean value of the HIE group in the first 3 days was as follows: 2438.64 ± 1187.56 U/l first day, 3043.5 ± 2333.53 U/l second day and 1265.6 ± 234.64 U/l third day of life.

Comparison of retinal thickness between HIE children and CTL group

Macular retinal thickness 3 mm, 6 mm and total were lower in the HIE group compared to the CTL group (p = 0.001, p = 0.039, and p = 0.020). Analysis of individual retinal layers revealed a difference in MNFL3 mm, 6 mm and total (p = 0.002, p = 0.035, and p = 0.008), which were reduced in HIE children. IPL 3 mm and total were lower in the HIE group than in the CTL group (p = 0.02, p = 0.035). IPL 6 mm was not significantly reduced in subjects within the HIE group (p = 0.077). Measurement of the inner retinal layers 3 mm, 6 mm and total confirmed that the damage in HIE children affects mainly the inner retina (p = 0.007, p = 0.05, and p = 0.024), while outer retinal layers thickness 3 mm, 6 mm and total was not different between the HIE and CTL groups (p = 0.568, p = 0.393, and p = 0.463). Finally, PNFL thickness was lower in the HIE group than in the CTL group (p = 0.008) (Tables 2 and 3 and Fig. 2).
Comparison of retinal thickness between HIE subgroups and CTL group

Macular retinal thickness 3 mm was lower in the SII-III/TH+, SII-III/TH- and SI/TH-subgroups compared to the CTL group ($p = 0.001$, $p = 0.021$, and $p = 0.045$). Furthermore, total macular retinal thickness was reduced in the SII-III/TH+ subgroup compared to the CTL group ($p = 0.008$). Analysis of individual retinal layers revealed a lower value of MNFL 3 mm, 6 mm and total in the SII-III/TH+ subgroup compared to the CTL group ($p = 0.001$, $p = 0.014$, and $p = 0.010$); moreover, MNFL 6 mm were reduced in the SII-III/TH-subgroup compared to the CTL group ($p = 0.034$). Hypothermic HIE children showed a reduction of GCL 3 mm compared to the CTL groups ($p = 0.01$). Finally, PNFL thickness was lower in the SII-III/TH+ and SII-III/TH- subgroups than in the CTL group ($p = 0.028$, $p = 0.007$). Differences in retinal thickness and peripapillary nerve fibre layers in the SII-III/TH+, SII-III/TH- and SI/TH-subgroups were not significant. The values of retinal thickness are reported in Table 2 and Fig. 3. Standard error of the mean and confidence intervals are shown in Table 3.

Correlations between retinal thickness measured with SD-OCT and systemic parameters

In the HIE group, GCL 3 mm correlated positively with total bilirubin ($p < 0.05$) and negatively with LDH and PCR ($p < 0.01$). Greater thickness of GCL total was associated with higher total bilirubin and lower LDH ($p < 0.05$). GCL 6 mm does not correlate with systemic parameters. Higher thickness of PNFL correlated with higher albumin ($p < 0.01$) and lower PCR ($p < 0.05$) (Fig. 4). Furthermore, lower PNFL thickness was observed in children with alterations at cerebral ultrasound (hyperechogenicity of periventricular white matter, impaired white/grey matter differentiation and/or slit-like ventricles) ($p = 0.046$) (Fig. 5).

APGAR score, pH and base excess in funiculus blood at birth, apnoea duration, cerebral MRI ischaemic lesions and PEV latency did not have a statistically significant correlation with retinal layers thickness, neither for total population, nor for subgroups ($p > 0.05$).

Discussion

To the best of our knowledge, this is the first study that evaluates long-term retinal damage with SD-OCT in children with hypoxic–ischaemic encephalopathy at birth, stratifying the population according to the severity of the hypoxic insult and the hypothermic treatment for HIE.
Table 2  Total retinal thickness and individual retinal layer thickness for groups enrolled in the study

|                        | HIE group (mean ± standard deviation) | SII-III/TH+ subgroup (mean ± standard deviation) | SII-III/TH- subgroup (mean ± standard deviation) | SI/TH- subgroup (mean ± standard deviation) | CTL group (mean ± standard deviation) |
|------------------------|---------------------------------------|-------------------------------------------------|-----------------------------------------------|---------------------------------------------|---------------------------------------|
| Total retinal thickness (μm) | 3 mm, 312.74 ± 11.29* | 311.30 ± 11.04* | 313.27 ± 8.54* | 314.53 ± 14.68* | 328.42 ± 18.14* |
|                        | 6 mm, 301.26 ± 11.03* | 302.90 ± 8.75* | 299.66 ± 9.57* | 300.34 ± 15.73* | 307.09 ± 10.89* |
|                        | Total, 312.74 ± 11.29* | 311.30 ± 11.04* | 313.26 ± 8.54* | 314.53 ± 14.68* | 318.49 ± 10.18* |
| Macular nerve fibre layer (μm) | 3 mm, 19.73 ± 1.56* | 19.24 ± 1.46* | 20.25 ± 1.12* | 19.98 ± 1.98* | 21.04 ± 1.37* |
|                        | 6 mm, 33.64 ± 3.98* | 33.47 ± 3.58* | 33.50 ± 2.92* | 34.06 ± 5.65* | 36.11 ± 3.17* |
|                        | Total, 25.08 ± 2.40* | 24.70 ± 2.28* | 25.30 ± 1.62* | 25.46 ± 3.29 | 26.69 ± 1.79* |
| Ganglion cell layer (μm) | 3 mm, 51.20 ± 4.85* | 50.31 ± 1.12 | 52.81 ± 2.49* | 50.91 ± 6.14* | 54.04 ± 2.81* |
|                        | 6 mm, 37.28 ± 2.87* | 37.89 ± 2.55 | 36.92 ± 2.41 | 36.68 ± 3.78 | 38.68 ± 2.48 |
|                        | Total, 41.08 ± 3.18* | 40.83 ± 3.41 | 41.62 ± 1.97 | 40.90 ± 4.01 | 42.76 ± 2.17 |
| Inner plexiform layer (μm) | 3 mm, 41.92 ± 3.34* | 41.50 ± 3.77 | 42.27 ± 1.58 | 42.23 ± 4.14 | 43.43 ± 2.09 |
|                        | 6 mm, 30.30 ± 2.26 | 30.86 ± 1.97 | 29.94 ± 2.01 | 29.80 ± 2.88 | 31.23 ± 1.89 |
|                        | Total, 34.43 ± 2.23* | 34.41 ± 2.31 | 34.36 ± 1.64 | 34.54 ± 2.81 | 35.38 ± 1.62 |
| Inner nuclear layer (μm) | 3 mm, 41.12 ± 2.89 | 41.71 ± 3.61 | 40.06 ± 1.89 | 41.30 ± 2.29 | 41.98 ± 2.72 |
|                        | 6 mm, 35.53 ± 2.03 | 36.33 ± 2.04 | 34.60 ± 1.59 | 35.23 ± 2.08 | 35.90 ± 2.55 |
|                        | Total, 36.07 ± 2.20 | 36.64 ± 2.64 | 35.06 ± 1.51 | 36.23 ± 1.78 | 36.46 ± 2.12 |
| Outer plexiform layer (μm) | 3 mm, 34.16 ± 4.05 | 36.31 ± 4.38 | 32.83 ± 3.43 | 32.11 ± 2.25 | 33.88 ± 4.74 |
|                        | 6 mm, 27.64 ± 1.96 | 28.33 ± 2.15 | 27.21 ± 2.01 | 26.98 ± 1.22 | 27.61 ± 2.51 |
|                        | Total, 30.54 ± 2.86 | 32.02 ± 3.06 | 29.41 ± 2.50 | 29.35 ± 1.69 | 30.19 ± 3.37 |
| Outer nuclear layer (μm) | 3 mm, 68.35 ± 7.80 | 65.90 ± 7.85 | 69.54 ± 7.46 | 71.05 ± 7.56 | 69.90 ± 7.13 |
|                        | 6 mm, 59.24 ± 5.68 | 59.01 ± 5.55 | 59.17 ± 5.92 | 59.70 ± 6.16 | 59.53 ± 5.17 |
|                        | Total, 66.24 ± 6.58 | 64.71 ± 6.66 | 67.16 ± 6.28 | 67.75 ± 6.85 | 67.41 ± 6.05 |
| Retinal pigment epithelium (μm) | 3 mm, 13.18 ± 1.20 | 13.14 ± 1.16 | 13.21 ± 1.34 | 13.23 ± 1.22 | 13.23 ± 1.20 |
|                        | 6 mm, 12.16 ± 0.99 | 12.06 ± 0.91 | 12.33 ± 1.18 | 12.14 ± 0.97 | 12.22 ± 1.01 |
|                        | Total, 13.09 ± 1.03 | 13.02 ± 1.04 | 13.17 ± 1.18 | 13.13 ± 0.92 | 13.12 ± 1.02 |
| Inner retinal layers (μm) | 3 mm, 256.55 ± 13.34* | 255.00 ± 14.35 | 257.77 ± 8.81 | 257.77 ± 16.41 | 264.14 ± 10.77 |
|                        | 6 mm, 223.61 ± 11.16* | 225.89 ± 9.01 | 221.21 ± 9.77 | 222.50 ± 15.42 | 229.13 ± 10.41 |
|                        | Total, 233.28 ± 11.13* | 233.15 ± 11.17 | 232.59 ± 8.24 | 234.24 ± 14.39 | 238.65 ± 9.40 |
| Outer retinal layers (μm) | 3 mm, 80.01 ± 2.03 | 79.36 ± 1.47 | 80.63 ± 2.14 | 80.39 ± 2.52 | 80.26 ± 1.84 |
|                        | 6 mm, 77.45 ± 1.43 | 76.88 ± 0.89 | 78.08 ± 1.59 | 77.70 ± 1.69 | 77.86 ± 1.93 |
|                        | Total, 79.69 ± 1.72 | 79.00 ± 1.21 | 80.37 ± 1.88 | 80.07 ± 1.98 | 79.98 ± 1.78 |
| Peripapillary circular scans of nerve fibres (μm) | 108.68 ± 10.70* | 109.06 ± 7.79* | 108.31 ± 7.83* | 108.40 ± 16.76 | 114.27 ± 6.81 |

* Statistically significant over the control group
|                        | HIE group | SII-III/TH+ subgroup | SII-III/TH- subgroup | SI/TH- subgroup | CTL group |
|------------------------|-----------|----------------------|----------------------|-----------------|-----------|
| **Total retinal thickness (μm)** |           |                      |                      |                 |           |
| 3 mm                   | 312.74 ± 1.76* | 311.30 ± 2.60*       | 313.27 ± 2.47*       | 314.53 ± 4.43*  | 328.42 ± 2.94 |
|                        | 309.18–316.31 | 305.81–316.79        | 307.84–311.70        | 304.67–324.38   | 322.46–334.39 |
| 6 mm                   | 301.26 ± 1.72* | 302.90 ± 2.06        | 299.66 ± 2.76        | 300.34 ± 4.74   | 307.09 ± 1.77 |
|                        | 297.78–304.75 | 298.55–307.25        | 293.58–305.75        | 289.77–310.91   | 303.52–310.68 |
| **Total**              | 312.74 ± 1.76* | 311.30 ± 2.60*       | 313.27 ± 2.47*       | 314.53 ± 4.43*  | 318.49 ± 1.65 |
| **Macular nerve fibre layer (μm)** |           |                      |                      |                 |           |
| 3 mm                   | 19.73 ± 0.24* | 19.24–20.22          | 19.24 ± 0.34*        | 19.53–20.96     | 21.04 ± 0.22 |
|                        | 19.73–20.22 | 19.24–20.22          | 19.53–20.96          | 21.04–21.50     | 20.60–21.50 |
| 6 mm                   | 33.64 ± 0.62* | 32.38–34.90          | 31.69–35.25          | 30.27–37.86     | 36.11 ± 0.51 |
|                        | 33.64–34.90 | 32.38–34.90          | 31.69–35.25          | 30.27–37.86     | 35.06–37.15 |
| **Total**              | 25.08 ± 0.37* | 24.32–25.84          | 23.56–25.83          | 23.25–27.68     | 26.69 ± 0.29 |
| **Ganglion cell layer (μm)** |           |                      |                      |                 |           |
| 3 mm                   | 51.20 ± 0.76* | 49.67–52.73          | 50.31 ± 1.21*        | 50.91 ± 1.85    | 54.04 ± 0.46 |
|                        | 49.67–52.73 | 49.67–52.73          | 50.31–1.21           | 50.91–1.85      | 53.11–54.96 |
| 6 mm                   | 37.28 ± 0.45* | 36.37–38.19          | 36.62–39.15          | 34.15–39.22     | 38.68 ± 0.40 |
|                        | 36.37–38.19 | 36.37–38.19          | 36.62–39.15          | 34.15–39.22     | 37.86–39.49 |
| **Total**              | 41.08 ± 0.50* | 39.78–42.09          | 40.37–42.87          | 38.20–43.59     | 42.76 ± 0.35 |
| **Inner plexiform layer (μm)** |           |                      |                      |                 |           |
| 3 mm                   | 41.92 ± 0.52* | 40.87–42.97          | 41.50 ± 0.89         | 41.27–43.27     | 43.43 ± 0.34 |
|                        | 40.87–42.97 | 40.87–42.97          | 41.50–0.89           | 41.27–43.27     | 42.74–44.12 |
| 6 mm                   | 30.30 ± 0.35 | 29.59–31.02          | 29.88–31.84          | 28.66–31.21     | 31.23 ± 0.31 |
|                        | 29.59–31.02 | 29.59–31.02          | 29.88–31.84          | 28.66–31.21     | 30.61–31.85 |
| **Total**              | 34.43 ± 0.35* | 33.72–35.14          | 34.36 ± 0.47         | 33.32–35.40     | 35.38 ± 0.26 |
| **Inner retinal layers (μm)** |           |                      |                      |                 |           |
| 3 mm                   | 256.55 ± 2.08* | 252.34–260.77        | 257.77 ± 2.54        | 257.77 ± 4.95   | 264.14 ± 1.75 |
|                        | 252.34–260.77 | 252.34–260.77        | 257.77–2.54          | 257.77–4.95     | 260.60–267.69 |
| 6 mm                   | 223.61 ± 1.74* | 220.09–227.13        | 221.12 ± 2.82        | 221.12–2.82     | 225.71–232.55 |
|                        | 220.09–227.13 | 220.09–227.13        | 221.12–2.82          | 221.12–2.82     | 225.71–232.55 |
| **Total**              | 233.28 ± 1.74* | 229.77–236.79        | 232.59 ± 2.38        | 232.59–2.38     | 235.56–241.74 |
| **Peripapillary circular scans of nerve fibres (μm)** | | | | | |
| 108.68 ± 1.69* | 105.25–112.09 | 109.06 ± 1.84* | 105.19–112.94 | 108.31 ± 2.36* | 112.03–116.51 |

* Statistically significant over the control group
We studied HIE children and we found that the thicknesses of PNFL, MNFL, GCL and IPL were reduced, without any subsequent visual functional damage. Among the subgroups, thickness reduction of inner retinal layers can be found in patients with Sarnat score II-III compared to healthy subjects, regardless of any therapeutic hypothermic treatment. Experimental studies on murine models report damage to the inner retinal layers with HIE (ganglion cell layer, inner plexiform layer and inner nuclear layer) [11–13]. Mangalesh et al. found ganglion cell and peripapillary nerve fibre layer impairment assessing HIE children with SD-OCT within the first two weeks of hypoxic–ischaemic insult [15]. Osborn et al. showed greater susceptibility of inner retina to lack of oxygen compared to outer retinal layers. Outer retinal layers and photoreceptors receive blood supply directly from the central retinal artery and indirectly from the choriocapillaris, and this double blood supply is protective against hypoxic–ischaemic damage. Inner retinal layers, on the other hand, are vascularized by the central retinal artery which supplies the macula. Central retinal artery occlusion damages mainly the inner retinal layers, while outer retinal layers damage is related to choriocapillaris ischemia or to the separation of the photoreceptor layer from the retinal pigment epithelium [16].

For some statistically significant values of retinal thickness, there was a minimal overlap of confidence intervals and of standard error of mean [17]. This could affect clinical significance of our results, although the overlaps were less than 1 μm. In addition, clinical significance of our study was difficult to assess, due to absence of similar analysis and for the limited population enrolled.

In many studies, visual loss in HIE children was attributed to cortical visual impairment, due to trans-synaptic retrograde damage following occipital cortex impairment. However, this assertion has been questioned, because visual damage frequently did not correlate with the severity of magnetic resonance signs of injury [13]. Chan et al., evaluating rats with neonatal hypoxia ischemia through magnetic resonance, demonstrated that damage to retinocollicular and retinogeniculate pathways occurs due to an anterograde process starting from the eye. Although both eyes and visual pathways were damaged in HIE rats, the contribution of said damage to visual impairment was not defined [18]. Mangalesh et al. found an association between retinal defects and MRI alterations evaluating 8 HIE children: newborns with low-grade MRI changes had no retinal findings, children with intermediate MRI damage had subretinal fluid or macular cystic spaces, while children with more severe MRI alterations had parafoveal cystoid spaces and

![Comparison of retinal thicknesses (total macular thickness, macular nerve fibre layer, ganglion cells layer and peripapillary nerve fibre layer) between the HIE group and control group](image-url)
loss of GCL/RNFL in the macula. Moreover, the author pointed out that children with intermediate MRI damage showed a different kind of retinal damage, suggesting a possible primitive eye injury independent from brain damage [15]. In our study, the enrolled population did not present visual impairment, as we measured a best corrected visual acuity of 10/10 in all patients. Then, we evaluated if there was a correlation between the reduction of retinal thickness in SD-OCT and MRI ischaemic areas. This correlation was not detected, suggesting a possible primary retinal damage in HIE children. In any case, we cannot exclude a retrograde or anterograde damage component, because OCT retinal changes were in the order of magnitude of microns, while conventional magnetic resonance has a resolution of 1 mm [19].

In the subgroups analysis, a statistically significant difference of inner retinal layers thickness and peripapillary nerve fibre was observed between HIE children with Sarnat score II-III with or without hypothermic treatment and healthy patients. There was
no difference between HIE patients with Sarnat score I and healthy children. Retinal thickness was not different in children with Sarnat score II-III who did or did not receive hypothermia suggesting that TH was not protective against retinal damage. In murine models, retinal damage correlated with hypoxia severity at birth, with a progressive reduction of inner retinal layers thickness as hypoxia severity increased [11]. Rey-Funes et al. showed that therapeutic hypothermia was protective against inner retinal damage, while in rats with perinatal asphyxia that were not subjected to therapeutic hypothermia, there was an alteration of the ganglion cell layer, no neurodegenerative aspects of this layer were observed in the hypothermic group [12]. The discrepancy with the outcomes of the present study may be due to differences with animal models and to selection bias. Only patients able to undergo a complete ophthalmological evaluation were enrolled, thus excluding those with severe functional disabilities following hypoxic–ischaemic encephalopathy. Patients with Sarnat score II or III not subjected to hypothermia that were excluded from the study may possibly have greater damage to the inner retina. This may explain the absence of differences of inner retinal layers thickness between the SII-III/TH- subgroup and children treated with hypothermia. This was not an issue in rat studies, where the retinal thicknesses of all animals were evaluated. Furthermore, hypoxic conditions at birth may vary for each child: apnoea duration, comorbidities and causes of HIE may affect the outcome of ocular and cerebral damage. In experimental models, hypoxic–ischaemic damage was standardised for all the enrolled animals, producing homogeneous results in the samples.

Several correlations emerged by comparing retinal thickness and peripapillary nerve fibre layer with systemic parameters related to the severity of neonatal hypoxic–ischaemic damage. This emphasises how ocular damage fits into a complex damage system resulting from HIE.

C-reactive protein is an acute phase protein whose levels increase with the severity of encephalopathy. Therapeutic hypothermia results in a slower increase in CRP, but cooled children presented a later and higher peak of this value. A greater increase characterised patients with multiorgan failure [20]. LDH values are higher in patients with grey matter abnormalities, rendering it a predictive biomarker of neurodevelopmental prognosis in HIE children [21]. In our population, mean values of LDH and CRP levels in the first three days of life were higher in children with greater damage to ganglion cells layer, while peripapillary nerve fibre reduction was related only to CRP increase. CRP mean values increased progressively in HIE children during the first 4 days of life, while it began to fall on the fifth day. Unfortunately, the mean values of single days were distorted by the absence of correlation of retinal damage with the duration of apnoea, pH and excess base and index related to the first phase of damage.

In HIE children, higher total bilirubin is associated with greater ganglion cell thickness. Bilirubin is formed by the degradation of heme. Low bilirubin concentration is protective towards the central nervous system, acting as an antioxidant, while it is neurotoxic at high levels [26, 27]. Total bilirubin values are lower in HIE children compared to healthy newborns, probably because it is consumed for its antioxidant effect in newborns with severe oxidative stress [28]. Its protective effect has been also evaluated in the eye: bilirubin antioxidant effect has been assessed in retinopathy of prematurity, but results disagree in the studies [29–31]. In our study, a lower ganglion cell damage was present in children with higher levels of bilirubin, which could exert its protective antioxidant effect on free radicals produced in the retina during the reperfusion phase.

Albumin maintains osmotic blood pressure and transports different molecules in the bloodstream. It also possesses an
antioxidant effects, playing a role in neuron survival during development, especially in children with suffering at birth [32]. Albumin administration in HIE children reduces cerebral oedema and improves symptoms associated to encephalopathy [33]. Cerebral oedema can be assessed by cerebral ultrasound, a non-invasive and low-cost method that allows central nervous system evaluation. HIE children compared to the CTL group present an increase in white matter echogenicity compared to to grey matter due to cerebral oedema and possible necrosis of nervous tissue [34]. Findings such as slit-like ventricles are also suggestive of cerebral oedema [35]. Our study, lower albumin and cerebral ultrasound signs of cerebral oedema correlate with lower peripapillary nerve fibre layer thickness. We can hypothesise that the damage is related to the presence of cerebral oedema at birth, resulting in deterioration and reduction of optic nerve fibres.

Our study has numerous limitations: non-homogeneity of ages in the comparison between subgroups, exclusion of patients with severe outcomes deriving from HIE, non-execution of tests for assessment of visual quality (microperimetry, visual field) and electrophysiology tests because the smaller patients would not have the necessary collaboration, the assessment of ischaemic brain lesions regardless their location.

**Conclusion**

In our study, children with neonatal moderate and severe HIE had a slight reduction in the inner retinal layer thickness as shown in murine models, which did not correspond to a visual acuity impairment. These results were found in a population with neonatal HIE without systemic or neurologic long-term sequelae. Hypothermic treatment did not appear to be protective against ocular hypoxic–ischaemic insults, although this may be due to a selection bias. The damage to the inner retinal layers is related to higher CRP and LDH levels in the early days of life. Cerebral oedema may lead to peripapillary nerve fibre layer impairment. HIE subjects have a lower functional reserve of ganglion cells and nerve fibre layer, which could make them more susceptible in adulthood to diseases that damage inner retinal layers, such as glaucoma or optic neuritis. Further studies are needed to understand the pathophysiology of retinal damage in subjects with neonatal hypoxic–ischaemic injury. It would be interesting to assess possible retinal sensitivity damage (e.g. with microperimetry or electroretinography) related to ganglion cell and peripapillary nerve fibre layer undetectable with visual acuity testing alone. The identification of subclinical retinal damage in HIE children without long-term sequelae makes necessary the assessment of children with hypoxic–ischaemic damage outcomes to evaluate their eye impairment and whether it correlates with visual acuity impairment.

**Author's contribution** Study conception and design were performed by S. Pignatto and L. Grego. All authors contributed to material preparation and data collection and analysis. The first draft of the manuscript was written by L. Grego, and all authors commented and reviewed the manuscript. All authors read and approved the final manuscript.

**Funding** Open access funding provided by Università degli Studi di Udine within the CRUI-CARE Agreement.

**Compliance with ethical standards**

**Conflict of interest** PL is a consultant for Bayer, Centervue, Novartis Pharma AG, outside the submitted work. All authors, except PL, certify that they have no affiliations with or involvement in any organisation or entity with any financial interest (such as honoraria; educational grants; participation in speakers’ bureaus; membership, employment, consultancies, stock ownership, or other equity interest and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript.

**Ethical approval** All procedures performed in the study involving human participants were in accordance with the ethical standards of the regional ethics committee (CEUR) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

**Informed consent** Informed consent was obtained from parents and tutors of all individual participants included in the study.

**Abbreviations** HIE, hypoxic–ischaemic encephalopathy; TH, therapeutic hypothermia; MRI, magnetic resonance imaging; CT, computed tomography; SD-OCT, spectral-domain optical coherence tomography; HIE group, hypoxic–ischaemic encephalopathy group; CTL group, control group; SII-III/TH- subgroup, Sarnat score II-III and treated with hypothermia; SII-III/TH- subgroup, Sarnat score II-III and not treated with hypothermia; SII/TH- subgroup, Sarnat score II and not treated with hypothermia; MNFL, macular nerve fibre layer; GCL, ganglion cell layer; IPL, inner plexiform layer; INL, inner nuclear layer; OPL, outer plexiform layer; ONL, outer nuclear layer; RPE, retinal pigment epithelium; IRL, inner retinal layers; ORL, outer retinal layers; PNFL, peripapillary nerve fibre layer; ETDRS, Early Treatment Diabetic Retinopathy Study; VEP, visual evoked potentials flashes; MCV, mean corpuscular volume; MCHC, mean corpuscular haemoglobin concentration; CRP, C reactive protein; LDH, lactate dehydrogenase; SGOT, serum glutamic oxaloacetic transaminase; SGPT, serum glutamic pyruvate transaminase

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
References

1. Martin JR, Fanaroff AA, Walsh MC (2011) Fanaroff and Martin’s neonatal-perinatal medicine E-book: diseases of the fetus and infant, 9th. Elsevier, p 953

2. Allen KA, Brandon DH (2011) Hypoxic ischemic encephalopathy: pathophysiologic and experimental treatments. Newborn Infant Nurs Rev 11(3):125–133. https://doi.org/10.1053/sani.2011.07.004

3. Sarnat HB, Sarnat MS (1976) Neonatal encephalopathy following fetal distress. A clinical and electroencephalographic study. Arch Neurol 33(10):696–705. https://doi.org/10.1001/archneur.1976.00500100030012

4. Wachtel EV, Verma S, Mally PV (2019) Update on the current management of newborns with neonatal encephalopathy. Curr Probl Pediatr Adolesc Health Care 29:100636. https://doi.org/10.1016/jCPPeds.2019.07.001

5. Dickey EJ, Long SN, Hunt RW (2011) Hypoxic ischemic encephalopathy—what can we learn from humans? J Vet Intern Med 25(6):1231–1240. https://doi.org/10.1111/j.1939-1676.2011.00818

6. Hoyt CS (2007) Brain injury and the eye. Eye (Lond) 21(10):1285–1289. https://doi.org/10.1038/sj.eye.6700364

7. Hoyt CS (2003) Visual function in the brain-damaged child. Eye 17:371–386. https://doi.org/10.1038/sj.eye.6700364

8. Cioni G, Fazzi B, Ipata AE, Canapinchi R, van Hof-van Duin J (1996) Correlation between cerebral visual impairment and magnetic resonance imaging in children with neonatal encephalopathy. Dev Med Child Neurol 38(2):120–132. https://doi.org/10.1111/j.1469-8749.1996.tb12083

9. Lambert SR, Hoyt CS, Jan JE, Barkovich J, Flodmark O (1987) Visual recovery from hypoxic cortical blindness during childhood. Computed tomographic and magnetic resonance imaging predictors. Arch Ophthalmol 105(10):1371–1377. https://doi.org/10.1001/archopht.1987.0160010007300

10. Dutton GN, McKillop ECA, Saaidkisimova S (2006) Visual problems as a result of brain damage in children. Br J Ophthalmol 90(8):932–933. https://doi.org/10.1136/bjophthal.2006.059349

11. Jung S, Polosa A, Lachapelle P, Winkmair P (2015) Visual impairments following term neonatal encephalopathy: do retinal impairments also play a role? Invest Ophthalmol Vis Sci 56:5182–5193. https://doi.org/10.1167/iovs.15-16407

12. Rey-Funes M, Ibarra ME, Dorfman VB, López EM, López-Costa JJ, Coirini H, Loidl CF (2010) Hypothermia prevents the development of ischemic proliferative retinopathy induced by severe perinatal asphyxia. Exp Eye Res 90(1):113–120. https://doi.org/10.1016/j.exer.2009.09.019

13. Huang HM, Huang CC, Hung PL, Chang YC (2012) Hypoxic-ischemic retinal injury in rat pups. Pediatr Res 72(3):224–231. https://doi.org/10.1016/j.pr.2012.07.74

14. Tran-Viet D, Wong BM, Mangalesh S, Maldonado R, Cotten CM, Toth CA (2018) Handled spectral domain optical coherence tomography imaging through the undilated pupil in infants born preterm with hypoxic ischemic encephalopathy. Graefes Arch Clin Exp Ophthalmol 256(9):2039–2049. https://doi.org/10.1007/s00417-020-04738-0

15. Mangalesh S, Tran-Viet D, Pizoli C, Tai V, El-Dairi MA, Chen X, Edwards L, Finkle J, Freedman SF, Toth CA (2020) Subclinical retinal versus brain findings in infants with hypoxic ischemic encephalopathy. Graefes Arch Clin Exp Ophthalmol 258(9):2039–2049. https://doi.org/10.1007/s00417-020-04738-0

16. Osborne NN, Casson RJ, Wood JP, Chidlow G, Graham M, Melena J (2004) Retinal ischemia: mechanisms of damage and potential therapeutic strategies. Prog Retin Eye Res 23(1):91–147. https://doi.org/10.1016/S0364-5684(03)00012-0

17. Page P (2014) Beyond statistical significance: clinical interpretation of rehabilitation research literature. Int J Sports Phys Ther 9(5):726–736. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4197528/

18. Chan KC, Kancherla S, Fan SJ, Wu EX (2014) Long-term effects of neonatal hypoxia-ischemia on structural and physiological integrity of the eye and visual pathway by multimodal MRI. Invest Ophthalmol Vis Sci 56(1):1–9. https://doi.org/10.1167/iovs.14-24827

19. Lüsebrink F, Sciarra A, Mattern H, Yakupov R, Speck O (2017) T1-weighted in vivo human whole brain MRI dataset with an ultrahigh isotropic resolution of 250 μm. Sci Data 4:170032. https://doi.org/10.1038/sdata.2017.32

20. Cilla A, Arnaez J, Benavente-Fernández I, Ochoa C, Vega C, Lubínía-López S, García-Alix A (2019) Effect of hypothermia and severity of hypoxic-ischemic encephalopathy in the levels of C-reactive protein during the first 120 hours of life. Am J Perinatol 37(7):722–730. https://doi.org/10.1055/s-0039-1688818

21. Yum SK, Moon CJ, Youn YA, Sung IK (2017) Changes in lactate dehydrogenase are associated with central gray matter lesions in newborns with hypoxic-ischemic encephalopathy. J Matern Fetal Neonat Med 30(10):1177–1181. https://doi.org/10.1080/14767058.2016.1208745

22. Rath S, Narasimhan R, Lumsden C (2014) C-reactive protein (CRP) responses in neonates with hypoxic ischaemic encephalopathy. Arch Dis Child Fetal Neonatal Ed 99(2):F172. https://doi.org/10.1136/archdischild-2013-304367

23. Bhalaria US, Koehler RC, Kannan S (2015) Neuroinflammation and neuroimmune dysregulation after acute hypoxic-ischemic injury of developing brain. Front Pediatr 2:144. https://doi.org/10.3389/fped.2014.00014

24. Perlman JM (2006) Summary proceedings from the neurology group on hypoxic-ischemic encephalopathy. Pediatrics 117(3 Pt 2):S28–S33. https://doi.org/10.1542/peds.2005-0620E

25. Palmer C (1995) Hypoxic-ischemic encephalopathy: therapeutic approaches against microvascular injury, and role of neutrophils, PAF, and free radicals. Clin Perinatol 22(2):481–517. https://doi.org/10.1016/S0095-5108(18)30294-X

26. Doré S, Takahashi M, Ferris CD, Zakharie R, Hester LD, Guastella PA, and Free Radicals. Clin Perinatol 22(2):481–517. https://doi.org/10.1016/S0095-5108(18)30294-X

27. Kapitulnik J (2004) Bilirubin: an endogenous product of heme degradation with both cytotoxic and cytoprotective properties. Mol Pharmacol 66(4):773–779. https://doi.org/10.1124/mol.104.002832

28. Zou L, Yuan H, Liu Q, Lu C, Wang L (2019) Potential protective effects of bilirubin following the treatment of neonatal hypoxic-ischemic encephalopathy with hypothermia therapy. Biosci Rep 39(6):BSR20182332. https://doi.org/10.1042/BSR20182332

29. Kao JS, Dawson JD, Murray JC, Dagle JM, Berends SK, Gillen SB, Bell EF (2011) Possible roles of bilirubin and breast milk in protection against retinopathy of prematurity. Acta Paediatr 100(3):347–351. https://doi.org/10.1111/j.1651-2227.2010.02069

30. Heyman E, Ohlsson A, Girschek P (1989) Retinopatía de prematuridad y bilirrubina. N Engl J Med 320(4):256. https://doi.org/10.1056/NEJM198902123200204

31. De Jonge MH, Khuntia A, Maisels MJ, Bandagi A (1999) Bilirubin levels and severe retinopathy of prematurity in infants with estimated gestational ages of 23 to 26 weeks. J Pediatr 135(1):102–104. https://doi.org/10.1016/S0022-3476(99)70336-7

32. Choudhary M, Sharma D, Dabi D, Lamba M, Pandita A, Shastri S (2015) Hepatic dysfunction in asphyxiated neonates: prospective case-controlled study. Clin Med Insights Pediatr 9:1–6. https://doi.org/10.4137/CMPed.S21426
33. Gürkan F, Haspolat K, Yaramış A, Ece A (2001) Beneficial effect of human albumin on neonatal cerebral edema. Am J Ther 8(4): 253–254. https://doi.org/10.1097/00045391-200107000-00008
34. Pinto PS, Tekes A, Singhi S, Northington FJ, Parkinson C, Huisman TA (2012) White-gray matter echogenicity ratio and resistive index: sonographic bedside markers of cerebral hypoxic-ischemic injury/edema? J Perinatol 32(6):448–453. https://doi.org/10.1038/jp.2011.121
35. Salas J, Tekes A, Hwang M, Northington FJ, Huisman TAGM (2018) Head ultrasound in neonatal hypoxic-ischemic injury and its mimickers for clinicians: a review of the patterns of injury and the evolution of findings over time. Neonatology 114(3):185–197. https://doi.org/10.1159/000487913

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Affiliations

L. Grego1,2 · S. Pignatto1,2 · E. Busolini3 · N. Rassu1,2 · F. Samassa1,2 · R. Prosperi1,2 · C. Pittini3 · L. Cattarossi3 · Paolo Lanzetta1,2

1 Department of Medicine, Ophthalmology, University of Udine, Udine, Italy
2 Clinica Oculistica, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Ospedale Santa Maria della Misericordia, Piazzale Santa Maria della Misericordia, 15, Udine 33100, Italy
3 Patologia Neonatale - Azienda Sanitaria Universitaria Friuli Centrale (ASUFC) - Ospedale Santa Maria della Misericordia, Piazzale Santa Maria della Misericordia, 15, Udine 33100, Italy